Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Oligodendroglioma

NCT05512351 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Oligodendroglioma

Interventions

DRUG: Tislelizumab plus Bevacizumab

Sponsor

Henan Provincial People's Hospital